2 results
Approved WMOCompleted
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
Approved WMORecruiting
The primary objective is to compare the pharmacological profile of the magistral form of dexamphetamine sulphate to the pharmacological profile of the brand-name form of dexamphetamine (Tentin©) in adult patients diagnosed with attention deficit…